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NOTE: The funding organizations (including the product manufacturer) had no role in 
study design, data collection, analysis, or interpretation, or in the decision to publish 
results. The authors designed the project and funding was then sought to support its 




 •  Sites
	 	 	 –	 	Lehigh	Valley	Health	Network,	Allentown,	PA
	 	 	 –	 	Winthrop	University	Hospital,	Mineola,	NY
	 	 	 –	 	Stony	Brook	University	Medical	Center,	Stony	Brook,	NY
	 •	 	Inclusion criteria
	 	 	 –	 	Patients	undergoing	primary	or	repeat	cesarean	delivery
	 	 	 –	 	Age	≥18
	 •	  Exclusion Criteria
	 	 	 –	 	Planned	tubal	ligation
	 	 	 –	 	Infertility	resulting	in	≥	2	years	of	treatment	to	achieve	current	
pregnancy
	 	 	 –	 	Known	allergy	to	hyaluronic	acid
	 	 	 –	 	Pain	score	≥5	or	IV	narcotic	administration	within	two	(2)	hours	
prior	to	consent















































































Table 2. Subsequent Delivery Surgical Characteristics
Patient Characteristics HA-CMC (n=80) Control (n=92) p-Value
Urgency of cesarean, % 	 	 0.793
   Scheduled 78.8 76.1 	
   Non-emergent 20.0 20.7 	
   Emergent 1.3 3.3
Labor prior to operation, % 20.0 21.7 0.852
Rupture of membranes, % 6.3 8.7 0.579
Skin to delivery time (minutes) 8	(1-22) 8	(2-27) 0.973
Total operative time (minutes) 60	(22-112) 58	(15-123) 0.540
Diabetes  (%) 15	(1.3) 32	(1.2) 0.941
Cesarean procedure type, %		
   Low transverse 98.8 96.7 0.624
   Classical 1.3 2.2 0.999
Estimated blood loss (ml) 800	(500-2000) 800	(600-1500) 0.745
Overall complications, % (n) 8.8	(7)	 4.4	(4) 0.665
   Bladder injury 0.0 0.0 -
   Bowel injury 5.2	(4) 2.3	(2) 0.423
   Hysterectomy 0.0 0.0 -
   Intra-operative transfusion 1.3	(1) 1.1	(1) 0.999
   Placenta accreta 0.0 0.0 -
   Uterine rupture 0.0 0.0 -




































   Caucasian 68.2	(259) 70.6	(264)
   African-American 10.3	(39) 10.2	(38)
   Asian 3.7	(14) 4.8	(18)
   Latino 15.2	(59) 11.5	(43)
   Other race/ethnicity 2.4	(9) 2.7	(10)
Gestational age (weeks)* 38.7	+	1.9 38.7	+	3.9
Body-mass index (kg/m2)* 33.3	+	6.6 33.2	+	7.8
Number of previous cesareans** 1	(0,	3) 1	(0,	3)
Indication for cesarean, % (n)	
   Planned repeat cesarean 70.0	(266) 67.0	(250)
   Non-reassuring fetal heart rate 2.6	(10) 3.0	(11)
   Arrest of labor 5.5	(21) 3.2	(12)
   Failed induction 1.8	(7) 3.2	(12)
   Previous uterine surgery 1.8	(7) 2.4	(9)
   Malpresentation 14.2	(54) 13.9	(52)
   Abnormal placentation 1.3	(5) 2.7	(10)
   Multiple gestation 4.5	(17) 6.7	(25)
   Maternal infection 0.8	(3) 1.3	(5)
Diabetes (any), % of arm (n) 9.8	(37)	 11.8	(44)
   Type I 0.8	(3) 0.5	(2)
   Type II 1.0	(4) 0.5	(2)
   Gestational Diabetes, A1 4.5	(17) 4.8	(18)
   Gestational Diabetes, A2 3.4	(13) 5.6	(21)
Pre-operative hematocrit* 34.8	+	4.3 34.4	+	5.0
Pre-operative WBC count* 10.3	+	3.4 10.7	+	4.6
Pre-operative Tmax** (
oF) 97.8	+	1.0 97.9	+	0.9
Table 3. Subsequent Delivery Adhesion Data (Primary Outcome)
Adhesion Characteristics HA-CMC (n=80) Control (n=92) p-Value
Adhesion score* 2	(0-10) 2	(0-8) 0.647
Any adhesion (any location), % 75.6 75.9 0.999
Bowel adhesions, % 5.2 2.3 	
Uterus to fascie, % 36.4 26.7 	
Omentum to fascia, % 32.5 27.9 	
Omentum to uterus, % 18.2 23.3 	
Bladder to uterus, % 65.4 62.1 	
Other location, % 5.2 10.5 	
Severe adhesions, % 33.3 15.5 0.052
* Data	are	presented	as	median	(range),	and	compared	between	groups	based	on	the	two-
sample	median	test.
Figure 1. Adhesion Assessment Scoring
Location None Filmy Dense
Bowel 0 1 2
Uterus to fascia (anterior abdominal wall) 0 1 2
Omentum to fascia (anterior abdominal wall) 0 1 2
Omentum to uterus 0 1 2
Baldder to uterus 0 1 2
Other pelvic structure 0 1 2
* Minimum	total	score	=	0;	maximum	total	score	=	12
Adopted from Lyell et al. Obstetrics and Gynecology 2005 Aug;106(2): 
275-80.
Figure 2. CONSORT Patient Flow Diagram 
Assessed for eligibility (n=1670) 
Excluded  (n=862) 
   Not meeting inclusion criteria (n=403) 
   Declined to participate (n=444) 
   Other reasons (n=15) 
Analyzed for safety data (n=380) 
 Excluded from analysis (n=0) 
Records Reviewed (n=380) 
Telephone Interview Completed (n=103) 
Allocated to HA-CMC (n=380) 
 Received allocated intervention (n=380) 
 
Records Reviewed (n=373) 
Telephone Interview Completed (n=100) 
Allocated to routine closure (n= 373) 
 Received allocated intervention (n= 373) 
 
Analyzed for safety data (n= 373) 




Randomized (n= 753) 
Enrollment 
Consented (n=808) 
Not Randomized  (n=55) 
   Vaginal delivery (n=50) 
   Revoked consent (n=3) 
   Other reasons (n=2) 
Subsequent cesarean delivery (n=80) 
 Excluded from analysis (n=0) 
Subsequent cesarean delivery (n=92) 
 Excluded from analysis (n=0) 
